NEW YORK, March 18, 2013 /PRNewswire/ --
Lifshitz Law Firm announces that a class action suit was filed in the United States District Court for the Northern District of California, alleging that Affymax, Inc. ("Affymax" or the "Company") (AFFY) issued false and misleading statements to investors between December 8, 2011 and February 22, 2013 (the "Class Period") by failing to adequately disclose: (1) that the Company's FY 2012 financial guidance was materially overstated; (2) that reported sales of its primary drug product were not sustainable; and (3) that the defendants were materially overstating sales and understating the potential liabilities related to its primary drug product, including refunds and potential liability to injured patients.
Impax Laboratories Inc.
Lifshitz Law Firm announces that a class action suit was filed in the United States District Court for the Northern District of California on behalf of purchasers of Impax Laboratories Inc. ("Impax" or the "Company") (IPXL) between June 6, 2011 through March 4, 2013, inclusive (the "Class Period"). The Complaint alleges defendants misrepresented and/or failed to disclose that at its Hayward facility: (1) the Company failed to maintain proper quality control and manufacturing practices in violation of current GMP; (2) the Company failed to take proper remedial actions to correct quality control issues previously identified by the FDA in prior inspections; and (3) the Company failed to disclose the extent of the adverse impact the manufacturing deficiencies could have on the Company's ability to successfully launch its new drug, Rytary.
Lifshitz Law Firm announces that a class action suit was filed in the United States District Court for the District of Connecticut on behalf of all persons or entities who purchased Tangoe, Inc. ("Tangoe" or the "Company") (TNGO) securities between December 20, 2011 and September 5, 2012 (the "Class Period"). The Complaint alleges defendants misrepresented and/or failed to disclose that (1) the Company was overstating organic growth by underreporting the percentage of revenue derived from recent acquisitions; (2) the Company was not growing customers organically as its deferred implementation fees failed to grow; and (3) as a result of the above, the Company's financial statements were materially false and misleading at all relevant times.
Lifshitz Law Firm is a New York based law firm with significant experience representing investors in merger-related shareholder class actions, shareholder derivative actions, and securities fraud class actions. For more information about the firm, please visit our website at www.jlclasslaw.com.
ATTORNEY ADVERTISING. © 2013 Lifshitz Law Firm. The law firm responsible for this advertisement is Lifshitz Law Firm, 18 East 41st Street, New York, New York 10017, (212) 213-6222. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Joshua M. Lifshitz, Esq.
Lifshitz Law Firm
Email: [email protected]
SOURCE Lifshitz Law Firm